Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

New Engineered Spider Silk has Potential to Unseat Dragon Silk as World's Strongest Recombinant Silk Fiber


Posted on: 31 Oct 16

ANN ARBOR, Mich., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced it has created a new line of genetically engineered silkworms that rival the Company’s Dragon Silk™ for the title as world’s strongest and most flexible recombinant spider silk.   Based on early testing results, this new line has a high probability of delivering performance exceeding that of the record setting Dragon Silk line announced in 2015.  Over the next several months the Company will conduct a thorough evaluation and performance comparison between these two incredible materials. 

“This brand new transgenic is the result of more than a year of dedicated development and thousands of individual microinjections,” said COO Jon Rice.  “We used a completely different approach in designing this new line to solving the challenge of commercially scalable spider silk.  This different approach is perhaps most significant because it offers the possibility to create a super hybrid by merging it with Dragon Silk and other strains.” 

“Even as we ramp up the production of Dragon Silk™ to fulfil our government contract and supply product for industry, we are inventing the next generation of materials to penetrate new markets,” said Company Founder and CEO Kim Thompson.  “This laboratory breakthrough, so close on the heels of the launching of our production facility, emphasizes our lead in this burgeoning field,” continued Thompson.  

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter.

For more information about Spider Silk, check it out at www.kraiglabs.com/spider-silk.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

GlobeNewswire
globenewswire.com

Last updated on: 31/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.